ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) today announced that its board of directors has approved a share repurchase program that authorizes the company to repurchase up to $200 million of its outstanding common stock over the next 24 months. The repurchase program is designed to increase shareholder value and reflects the company’s confidence in the long-term value of its common stock.
